Neurobiological correlates of delusion: Beyond the salience attribution hypothesis

Neuropsychobiology

Volumn 66, Issue 1, 2012, Pages 33-43

  Pankow, Anne ^a   Knobel, Astrid ^a   Voss, Martin ^a   Heinz, Andreas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BERNSTEIN CENTER FOR COMPUTATIONAL NEUROSCIENCE   (Germany)

Author keywords

Brain imaging; Delusions; Dopamine; Functional and structural disconnection; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ADDICTION; AMYGDALOID NUCLEUS; ANISOTROPY; ANTICIPATION; ANXIETY; APATHY; ARTICLE; AVOLITION; BRAIN FORNIX; BRAIN NERVE CELL; CAPSULA INTERNA; COGNITION; CORPUS CALLOSUM; CORPUS STRIATUM; DELUSION; DIFFUSION TENSOR IMAGING; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HEBEPHRENIA; HIPPOCAMPUS; HUMAN; HYPOTHESIS; LIMBIC SYSTEM; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROIMAGING; PARANOIA; PARANOID SCHIZOPHRENIA; PERSECUTORY DELUSION; POSITIVE SYNDROME; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REWARD; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; STIMULUS RESPONSE; TEMPORAL CORTEX; TEMPORAL LOBE;

AMYGDALA; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; CEREBRAL CORTEX; DELUSIONS; DOPAMINE; DOPAMINERGIC NEURONS; FRONTAL LOBE; HUMANS; TEMPORAL LOBE;

EID: 84863928018     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000337132     Document Type: Article

References (73)

1. Jaspers K: Allgemeine Psychopathologie, 8 Aufl. Berlin, Springer, 1965.
2. Heinz A: Dopaminergic dysfunction in alcoholism and schizophrenia -psychopathological and behavioral correlates. Eur Psychiatry 2002; 17: 9-16.
3. Murray RM, Lewis SW: Is schizophrenia a neurodevelopmental disorder? BMJ (Clin Res Ed) 1987; 295: 681-682.
4. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
5. Heinz A, Weinberger DR: Schizophrenia: The neurodevelopmental hypothesis. Current Concepts in Psychiatry (Psychiatrie der Gegenwart). Berlin, Springer, 2000, pp 89-104.
6. Carlsson A, Waters N, Carlsson ML: Neurotransmitter interactions in schizophrenia -therapeutic implications. Biol Psychiatry 1999; 46: 1388-1395.
7. Heinz A, Saunders RC, Kolachana BS, Jones DW, Gorey JG, Bachevalier J, Weinberger DR: Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage. Synapse 1999; 32: 71-79.
8. Shenton ME, Dickey CC, Frumin M, Mc-Carley RW: A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52.
9. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS: Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160: 179-186.
10. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghorn JM: Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 1993; 11: 47-54.
11. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U: Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 1997; 349: 1735-1739.
12. Puri BK, Lekh SK, Nijran KS, Bagary MS, Richardson AJ: SPECT neuroimaging in schizophrenia with religious delusions. Int J Psychophysiol 2001; 40: 143-148.
13. Kohno T, Shiga T, Kusumi I, Matsuyama T, Kageyama H, Katoh C, Koyama T, Tamaki N: Left temporal perfusion associated with suspiciousness score on the Brief Psychiatric Rating Scale in schizophrenia. Psychiatry Res 2006; 147: 163-171.
14. Ragland JD, Valdez JN, Loughead J, Gur RC, Gur RE: Functional magnetic resonance imaging of internal source monitoring in schizophrenia: recognition with and without recollection. Schizophr Res 2006; 87: 160-171.
15. Russell TA, Reynaud E, Kucharska-Pietura K, Ecker C, Benson PJ, Zelaya F, Giampietro V, Brammer M, David A, Phillips ML: Neural responses to dynamic expressions of fear in schizophrenia. Neuropsychologia 2007; 45: 107-123.
16. Kwon JS, McCarley RW, Hirayasu Y, Anderson JE, Fischer IA, Kikinis R, Jolesz FA, Shenton ME: Left planum temporale volume reduction in schizophrenia. Arch Gen Psychiatry 1999; 56: 142-148.
17. Szeszko PR, Bilder RM, Lencz T, Pollack S, Alvir JM, Ashtari M, Wu H, Lieberman JA: Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Res 1999; 90: 1-15.
18. Nestor PG, Onitsuka T, Gurrera RJ, Niznikiewicz M, Frumin M, Shenton ME, McCarley RW: Dissociable contributions of MRI volume reductions of superior temporal and fusiform gyri to symptoms and neuropsychology in schizophrenia. Schizophr Res 2007; 91: 103-106.
19. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998; 155: 1711-1717.
20. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V: Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128-137.
21. Rao NP, Kalmady S, Arasappa R, Venkatasubramanian G: Clinical correlates of thalamus volume deficits in anti-psychotic-naive schizophrenia patients: a 3-Tesla MRI study. Indian J Psychiatry 2010; 52: 229-235.
22. Takahashi T, Zhou SY, Nakamura K, Tanino R, Furuichi A, Kido M, Kawasaki Y, Noguchi K, Seto H, Kurachi M, Suzuki M: Longitudinal volume changes of the pituitary gland in patients with schizotypal disorder and firstepisode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 177-183.
23. Whitford TJ, Farrow TF, Williams LM, Gomes L, Brennan J, Harris AW: Delusions and dorso-medial frontal cortex volume in first-episode schizophrenia: a voxel-based morphometry study. Psychiatry Res 2009; 172: 175-179.
24. Basser PJ, Mattiello J, LeBihan D: MR diffusion tensor spectroscopy and imaging. Biophys J 1994; 66: 259-267.
25. Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, Niznikiewicz M, Connor EE, Levitt JJ, Frumin M, Kikinis R, Jolesz FA, McCarley RW, Shenton ME: DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 2005; 26: 1109-1118.
26. Knobel A, Heinz A, Voss M: Imaging the deluded brain. Eur Arch Psychiatry Clin Neurosci 2008; 258(suppl 5):76-80.
27. Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD: Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res 2008; 98: 157-162.
28. Fujiwara H, Namiki C, Hirao K, Miyata J, Shimizu M, Fukuyama H, Sawamoto N, Hayashi T, Murai T: Anterior and posterior cingulum abnormalities and their association with psychopathology in schizophrenia: a diffusion tensor imaging study. Schizophr Res 2007; 95: 215-222.
29. Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM: Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 2008; 33: 976-984.
30. Kalus P, Buri C, Slotboom J, Gralla J, Remonda L, Dierks T, Strik WK, Schroth G, Kiefer C: Volumetry and diffusion tensor imaging of hippocampal subregions in schizophrenia. Neuroreport 2004; 15: 867-871.
31. Kalus P, Slotboom J, Gallinat J, Wiest R, Ozdoba C, Federspiel A, Strik WK, Buri C, Schroth G, Kiefer C: The amygdala in schizophrenia: a trimodal magnetic resonance imaging study. Neurosci Lett 2005; 375: 151-156.
32. Chan WY, Yang GL, Chia MY, Lau IY, Sitoh YY, Nowinski WL, Sim K: White matter abnormalities in first-episode schizophrenia: a combined structural MRI and DTI study. Schizophr Res 2010; 119: 52-60.
33. Zhou Y, Shu N, Liu Y, Song M, Hao Y, Liu H, Yu C, Liu Z, Jiang T: Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia. Schizophr Res 2008; 100: 120-132.
34. Kienast T, Heinz A: Dopamine and the diseased brain. CNS Neurol Disord Drug Targets 2006; 5: 109-131.
35. Schultz W, Dayan P, Montague PR: A neural substrate of prediction and reward. Science 1997; 275: 1593-1599.
36. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-291.
37. Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160: 13-23.
38. Conrad K: Die beginnende Schizophrenie. Stuttgart, Thieme, 1958.
39. Selten JP, Cantor-Graae E: Social defeat: risk factor for schizophrenia? Br J Psychiatry 2005; 187: 101-102.
40. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D: Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 2001; 12: 3683-3687.
41. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A: Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006; 29: 409-416.
42. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-8109.
43. Romaniuk L, Honey GD, King JR, Whalley HC, McIntosh AM, Levita L, Hughes M, Johnstone EC, Day M, Lawrie SM, Hall J: Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia. Arch Gen Psychiatry 2010; 67: 1246-1254.
44. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M: Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48: 627-640.
45. Corlett PR, Honey GD, Aitken MR, Dickinson A, Shanks DR, Absalom AR, Lee M, Pomarol-Clotet E, Murray GK, McKenna PJ, Robbins TW, Bullmore ET, Fletcher PC: Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry 2006; 63: 611-621.
46. Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC: Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 2007; 130: 2387-2400.
47. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A: Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006; 187: 222-228.
48. Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A: Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008; 196: 673-684.
49. Schlagenhauf F, Sterzer P, Schmack K, Ballmaier M, Rapp M, Wrase J, Juckel G, Gallinat J, Heinz A: Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 2009; 65: 1032-1039.
50. Phan KL, Wager TD, Taylor SF, Liberzon I: Functional neuroimaging studies of human emotions. CNS Spectr 2004; 9: 258-266.
51. Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, Smolka MN, Grunder G, Cumming P, Kumakura Y, Bartenstein P, Dolan RJ, Heinz A: Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci 2008; 11: 1381-1382.
52. Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Grunder G: Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/ positron emission tomography study. J Neurosci 2007; 27: 8080-8087.
53. Coltheart M: Cognitive neuropsychiatry and delusional belief. Q J Exp Psychol (Colchester) 2007; 60: 1041-1062.
54. Coltheart M: Delusional belief. Annu Rev Psychol 2011; 57: 72-76.
55. McKay R, Langdon R, Coltheart M: Models of misbelief: integrating motivational and deficit theories of delusions. Conscious Cogn 2007; 16: 932-941.
56. Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH: Toward a neurobiology of delusions. Prog Neurobiol 2010; 92: 345-369.
57. Gottesman L, Chapman LJ: Syllogistic reasoning errors in schizophrenia. J Consult Psychol 1960; 24: 250-255.
58. Murray GK: The emerging biology of delusions. Psychol Med 2011; 41: 7-13.
59. Fletcher PC, Frith CD: Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 2009; 10: 48-58.
60. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC: Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry 2008; 13: 239, 267-276.
61. Blackwood NJ, Howard RJ, Bentall RP, Murray RM: Cognitive neuropsychiatric models of persecutory delusions. Am J Psychiatry 2001; 158: 527-539.
62. Bentall RP, Kaney S: Content specific information processing and persecutory delusions: an investigation using the emotional Stroop test. Br J Med Psychol 1989; 62: 355-364.
63. Blackwood NJ, Bentall RP, Ffytche DH, Simmons A, Murray RM, Howard RJ: Persecutory delusions and the determination of selfrelevance: an fMRI investigation. Psychol Med 2004; 34: 591-596.
64. Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, Skerrett D, Phillips ML, David AS, Peduto A, Gordon E: Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry 2004; 161: 480-489.
65. Garety PA, Hemsley DR, Wessely S: Reasoning in deluded schizophrenic and paranoid patients. Biases in performance on a probabilistic inference task. J Nerv Ment Dis 1991; 179: 194-201.
66. Moritz S, Laudan A: Attention bias for paranoia-relevant visual stimuli in schizophrenia. Cogn Neuropsychiatry 2007; 12: 381-390.
67. Heinz A, Schlagenhauf F: Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010; 36: 472-485.
68. Makris N, Seidman LJ, Ahern T, Kennedy DN, Caviness VS, Tsuang MT, Goldstein JM: White matter volume abnormalities and associations with symptomatology in schizophrenia. Psychiatry Res 2010; 183: 21-29.
69. Mitelman SA, Torosjan Y, Newmark RE, Schneiderman JS, Chu KW, Brickman AM, Haznedar MM, Hazlett EA, Tang CY, Shihabuddin L, Buchsbaum MS: Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: a diffusion tensor imaging survey. Schizophr Res 2007; 92: 211-224.
70. Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S: The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 2008; 33: 473-479.
71. Walter H, Kammerer H, Frasch K, Spitzer M, Abler B: Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (Berl) 2009; 206: 121-132.
72. Rotarska-Jagiela A, van dV, V, Oertel-Knochel V, Uhlhaas PJ, Vogeley K, Linden DE: Resting-state functional network correlates of psychotic symptoms in schizophrenia. Schizophr Res 2010; 117: 21-30.
73. Gradin VB, Kumar P, Waiter G, Ahearn T, Stickle C, Milders M, Reid I, Hall J, Steele JD: Expected value and prediction error abnormalities in depression and schizophrenia. Brain 2011; 134: 1751-1764.